首页> 外国专利> COMBINED ACETYLCHOLINESTERASE INHIBITOR AND QUATERNARY AMMONIUM ANTIMUSCARINIC THERAPY TO ALTER PROGRESSION OF COGNITIVE DISEASES

COMBINED ACETYLCHOLINESTERASE INHIBITOR AND QUATERNARY AMMONIUM ANTIMUSCARINIC THERAPY TO ALTER PROGRESSION OF COGNITIVE DISEASES

机译:联合乙酰胆碱酯酶抑制剂和季铵盐止痛药治疗可改变认知疾病

摘要

A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
机译:一种将季铵抗胆碱能毒蕈碱受体拮抗剂与乙酰胆碱酯酶抑制剂联合给药以治疗认知障碍或急性del妄的方法。该疗法导致认知障碍或疾病的改变,即疾病进展的减慢。在一个优选的实施方案中,该疾病是路易体痴呆。还公开了用于季铵抗胆碱能毒蕈碱受体拮抗剂的新制剂。

著录项

  • 公开/公告号US2019314332A1

    专利类型

  • 公开/公告日2019-10-17

    原文格式PDF

  • 申请/专利权人 QAAM PHARMACEUTICALS LLC;

    申请/专利号US201916454862

  • 发明设计人 STEVEN A. RICH;

    申请日2019-06-27

  • 分类号A61K31/40;A61K31/435;A61K31/439;C07D451;C07D207/12;A61K31/27;A61K31/216;A61K31/137;A61K9/70;A61K9;A61K31/202;A61K31/201;A61K31/20;A61K31/438;A61K31/4015;A61K31/407;A61K31/165;A61K31/445;

  • 国家 US

  • 入库时间 2022-08-21 12:13:20

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号